Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma
JAMA · 13.05.2025 · 333 (18) · 1589
DOI: 10.1001/jama.2025.1132 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift JAMA, erschienen am 13.05.2025. Verfasst von Ye-Lin Liang und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of …. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Immune Checkpoint Inhibitors, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms. Die Arbeit wurde bisher 89-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Approximately 20% to 30% of patients with locoregionally advanced nasopharyngeal carcinoma (NPC) experience disease relapse despite definitive chemoradiotherapy. The programmed cell death 1 (PD-1) blockade camrelizumab has demonstrated considerable value in recurrent or metastatic NPC, while its role in locoregionally advanced NPC is unclear.
Objective
To evaluate the efficacy and safety of adjuvant camrelizumab for patients with locoregionally advanced NPC. Design, Setting, and Participants Randomized, open-label, multicenter, phase 3 clinical trial conducted from August 2018 to November 2021 at 11 centers in China and enrolling 450 patients with T4N1M0 or T1-4N2-3M0 NPC who had completed induction-concurrent chemoradiotherapy. The final date of follow-up was March 20, 2024.
Interventions
Patients were randomized (1:1) to receive adjuvant camrelizumab (200 mg intravenously once every 3 weeks for 12 cycles; n = 226) or observation (standard therapy group; n = 224). Main Outcomes and Measures The primary end point was event-free survival (freedom from distant metastasis, locoregional relapse, or death due to any cause). Secondary end points included distant metastasis–free survival, locoregional relapse–free survival, overall survival, safety, and health-related quality of life.
Results
Among the 450 participants (mean age, 45 [SD, 10] years; 24% women), after a median follow-up of 39 (IQR, 33-50) months, the camrelizumab group had a 3-year event-free survival rate of 86.9%, whereas the standard therapy group had a rate of 77.3% (stratified hazard ratio, 0.56; 95% CI, 0.36-0.89; P = .01). Grade 3 or 4 adverse events were reported in 23 patients (11.2%) in the camrelizumab and 7 (3.2%) in the standard therapy group. Reactive capillary endothelial proliferation was the most common adverse event related to camrelizumab, occurring in 85.8% of patients at grade 1 or 2, while 2% of patients had grade 3 or 4 events. There was no significant deterioration in quality of life associated with camrelizumab treatment. Conclusions and Relevance Adjuvant PD-1 blockade with camrelizumab significantly improved event-free survival with manageable toxicities, highlighting its potential role in the management of locoregionally advanced NPC. Trial Registration ClinicalTrials.gov Identifier: NCT03427827
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial C…
- Chinese Society of Clinical Oncology, Beijing, China.
- Department of Oncology, Xiangya Hospital, Central South University, Changsha, China.
- Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
- Department of Oncology, Panyu Central Hospital, Guangzhou, China.
- Department of Radiation Oncology, First People's Hospital of Foshan, Foshan, China.
Zitieren
APA
Liang, Y. L., Liu, X., Shen, L. F., Hu, G. Y., Zou, G. R., Zhang, N., Chen, C. B., Chen, X. Z., Zhu, X. D., Yuan, Y. W., Yang, K. Y., Jin, F., Hu, W. H., Xie, F. Y., Huang, Y., Han, F., Tang, L. L., Mao, Y. P., Lu, L. X., …, & Liu, N. (2025). Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma. JAMA, 333(18), 1589. https://doi.org/10.1001/jama.2025.1132
Vancouver
Liang YL, Liu X, Shen LF, Hu GY, Zou GR, Zhang N, et al. Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma. JAMA. 2025;333(18):1589. doi:10.1001/jama.2025.1132
BibTeX
@article{Liang2025,
author = {Liang, Ye-Lin and Liu, Xu and Shen, Liang-Fang and Hu, Guang-Yuan and Zou, Guo-Rong and Zhang, Ning and Chen, Chuan-Ben and Chen, Xiao-Zhong and Zhu, Xiao-Dong and Yuan, Ya-Wei and Yang, Kun-Yu and Jin, Feng and Hu, Wei-Han and Xie, Fang-Yun and Huang, Ying and Han, Fei and Tang, Ling-Long and Mao, Yan-Ping and Lu, Li-Xia and Sun, Rui and He, Yu-Xiang and Zhou, Yang-Ying and Long, Guo-Xian and Tang, Jie and Chen, Lu-Si and Zong, Jing-Feng and Jin, Ting and Li, Ling and Lin, Jie and Huang, Jing and Gong, Xiu-Yun and Zhou, Guan-Qun and Chen, Lei and Li, Wen-Fei and Chen, Yu-Pei and Xu, Cheng and Lin, Li and Huang, Shao-Hui and Huang, Sai-Wei and Wang, Ya-Qin and Huang, Cheng-Long and Feng, Hui-Xia and Hou, Min and Chen, Chun-Hua and Zheng, Su-Fen and Li, Ying-Qing and Hong, Shu-Bin and Jie, Yu-Sheng and Li, Hao and Yun, Jing-Ping and Zang, Sheng-Bing and Liu, Song-Ran and Lin, Qing-Guang and Li, Hao-Jiang and Tian, Li and Liu, Li-Zhi and Zhao, Hong-Yun and Li, Ji-Bin and Lin, Ai-Hua and Liu, Na},
title = {Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma},
journal = {JAMA},
year = {2025},
volume = {333},
number = {18},
pages = {1589},
doi = {10.1001/jama.2025.1132}
}
EUVIMED